GENinCode Plc

Equities

GENI

GB00BL97B504

Medical Equipment, Supplies & Distribution

Market Closed - London S.E. Other stock markets 11:35:09 2024-05-15 am EDT			5-day change	1st Jan Change
8.5 ^GBX	+4.62%		-5.56%	+61.90%

Apr. 04	GENinCode Plc Announces Publication by the American Journal of Preventive Cardiology of A Study on 'Polygenic Risk and Incident Heart Disease in a Large Multiethnic Cohort	CI
Mar. 21	GENinCode says ROCA recommended as ovarian cancer risk test in England	AN

GENinCode gets GBP57,000 in retail offer, well below maximum

December 28, 2023 at 03:50 am EST

GENinCode PLC - biotechnology company focused on prevention of cardiovascular disease - Raises GBP57,378 via a retail offer of 1.1 million shares at a price of 5 pence each. This is in addition to the placing and subscription raised on Thursday last week. At that time, it had said it hoped raise up to GBP1.0 million via the retail offer to existing shareholders. A total of 81.1 million new shares have been issued under all three equity raises, including 67.6 million placing shares and 12.4 million subscription shares. Total gross proceeds are GBP4.1 million. Admission of new shares is expected at the opening bell on January 10, taking the number of GENinCode shares in issue to 177.0 million shares.

Current stock price: last traded at 5.40p on Wednesday in London

12-month change: down 28%

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Latest news about GENinCode Plc

GENinCode Plc Announces Publication by the American Journal of Preventive Cardiology of A Study on 'Polygenic Risk and Incident Heart Disease in a Large Multiethnic Cohort	Apr. 04	CI
GENinCode says ROCA recommended as ovarian cancer risk test in England	Mar. 21	AN
GENinCode gets GBP57,000 in retail offer, well below maximum	Dec. 28	AN
GENinCode Raises GBP4 Million from Share Sale	Dec. 28	MT
GENinCode raises GBP4 million via placing and subscription	Dec. 21	AN
Genincode Plc Announces Placing And Subscription To Raise A Minimum Of £4.0 Mln	Dec. 21	RE
Aura eyes Tiris expansion; Kavango backs Pambili	Nov. 29	AN
GENinCode plc Agrees with the Food and Drug Administration to Create New Regulatory Class for Polygenic Risk scores and Transition Its Premarket Notification 510(K) Submission to A De Novo Pathway	Nov. 29	CI
EARNINGS: ASA interim profit plummets; Mycelx loss narrows, revenue up	23-09-20	AN
Earnings Flash (GENI.L) GENINCODE Reports H1 Revenue GBP950,000	23-09-20	MT
Earnings Flash (GENI.L) GENINCODE Posts H1 Loss GBX-3.33	23-09-20	MT
GENinCode Plc Provides Revenue Guidance for the Second Half of 2023	23-09-20	CI
GENinCode Plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-20	CI
Genincode plc Announces CARDIO inCode study on risk of incident Coronary Heart Disease	23-08-30	CI
GENinCode Shares Rise on FDA Filing for Heart Disease Test Kit	23-08-16	DJ
GENinCode Submits Premarket Notification for US Commercial Distribution of Polygenic Test Kit	23-08-16	MT
GENinCode plc Files its Premarket Notification with the Food and Drug Administration to Expand Its US Commercial Distribution of the Cardio InCode-Score Polygenic Test for the Risk Assessment and Prevention of Coronary Heart Disease	23-08-16	CI
Certain Ordinary Shares of GENinCode Plc are subject to a Lock-Up Agreement Ending on 23-JUL-2023.	23-07-22	CI
GENinCode Shares Rise Amid US Partnership with MedStar Health	23-07-19	MT
GENinCode and MedStar collaborate on coronary heart disease testing	23-07-19	AN
GENinCode Plc Announces Collaboration with MedStar Health	23-07-19	CI
GENinCode annual loss widens; focuses on US, EU, and NHS in UK	23-06-06	AN
GENinCode Plc Reports Earnings Results for the Full Year Ended December 31, 2022	23-06-06	CI
GENinCode Plc Reports Earnings Results for the Full Year Ended December 31, 2022	23-06-06	CI
GENinCode Plc Auditor Raises 'Going Concern' Doubt	23-06-04	CI

Chart GENinCode Plc

Duration

Period

More charts

Company Profile

GENinCode Plc is a United Kingdom-based predictive genetics company. The Company is engaged in the risk assessment, prediction, and prevention of cardiovascular disease (CVD). Its tests include Cardio Incode, Lipid Incode, Sudd Incode, Roca Test, Thrombo and Thrombo Incode Reproductive Health. The Company's product portfolio draws on advanced genomic precision testing using polygenic (multiple genes) technology, molecular testing, genotyping, sequencing, and AI bioinformatics to risk assess patient DNA. Its predictive technology provides patients and physicians with global preventative care and treatment strategies. Its products combine genetic and clinical data to risk-assess patients and provide healthcare practitioners with advanced clinical information to evaluate and predict the onset of cardiovascular disease. The Companyâs wholly owned subsidiaries include GENinCode S.L.U. and GENinCode U.S. INC.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-09-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for GENinCode Plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
GENINCODE PLC	+61.90%	18.09M
BIOMÉRIEUX	-4.62%	12.18B
DIASORIN S.P.A.	+8.48%	5.96B
LANTHEUS HOLDINGS, INC.	+27.58%	5.45B
AUTOBIO DIAGNOSTICS CO., LTD.	-6.28%	4.34B
10X GENOMICS, INC.	-52.91%	3.18B
ANDON HEALTH CO., LTD.	+12.93%	2.75B
MYRIAD GENETICS, INC.	+30.15%	2.3B
VITROLIFE AB	-3.80%	2.28B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-4.64%	1.92B

Diagnostic & Testing Substances